- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] MODULE 3: New Directions in the Management of UBC () - Jun 5, 2021 - Abstract #ASCO2021ASCO_5875;
The trial was registered on August 19, 2015 under identifier NCT02529553 with ClinicalTrials.gov. Available data from the Phase I/II CheckMate 032 trial of nivolumab alone or in combination with ipilimumab in the cohort of patients with advanced UBC Ongoing Phase III trials (eg, CheckMate 901, NILE) evaluating anti-PD-1/PD-L1 antibodies in combination with other systemic therapies as first-line therapy for patients with unresectable locally advanced or metastatic UBC Design, eligibility criteria and key endpoints of the ongoing Phase III PROOF 302 trial of the oral FGFR inhibitor infigratinib as adjuvant therapy for patients with MIBC harboring susceptible FGFR3 alterations Published research findings and ongoing evaluations of other FGFR-targeted agents (eg, pemigatinib, rogaratinib, vofatamab, LY3076226, futibatinib) in UBC Clinical rationale for the ongoing evaluation of enfortumab vedotin in combination with an immune checkpoint inhibitor as neoadjuvant therapy for cisplatin-eligible patients with MIBC (KEYNOTE-B15/EV-304) Potential role of the antibody-drug conjugate sacituzumab govitecan in heavily pretreated metastatic UBC Biologic rationale for the ongoing evaluations of the multi-receptor tyrosine kinase inhibitor cabozantinib in combination with one or more anti-PD-1/PD-L1 antibodies in UBC (eg, ABATE, ARCADIA, PemCab, ICONIC) Emerging targets (eg, ICOS, ATR) and other novel agents (eg, feladilimab, berzosertib) and strategies in clinical development for patients with UBC
- |||||||||| LY3076226 / Eli Lilly
Enrollment change, Metastases: A Study of LY3076226 in Participants With Advanced or Metastatic Cancer (clinicaltrials.gov) - Apr 17, 2020
P1, N=25, Completed,
Available data from the Phase I/II CheckMate 032 trial of nivolumab alone or in combination with ipilimumab in the cohort of patients with advanced UBC Ongoing Phase III trials (eg, CheckMate 901, NILE) evaluating anti-PD-1/PD-L1 antibodies in combination with other systemic therapies as first-line therapy for patients with unresectable locally advanced or metastatic UBC Design, eligibility criteria and key endpoints of the ongoing Phase III PROOF 302 trial of the oral FGFR inhibitor infigratinib as adjuvant therapy for patients with MIBC harboring susceptible FGFR3 alterations Published research findings and ongoing evaluations of other FGFR-targeted agents (eg, pemigatinib, rogaratinib, vofatamab, LY3076226, futibatinib) in UBC Clinical rationale for the ongoing evaluation of enfortumab vedotin in combination with an immune checkpoint inhibitor as neoadjuvant therapy for cisplatin-eligible patients with MIBC (KEYNOTE-B15/EV-304) Potential role of the antibody-drug conjugate sacituzumab govitecan in heavily pretreated metastatic UBC Biologic rationale for the ongoing evaluations of the multi-receptor tyrosine kinase inhibitor cabozantinib in combination with one or more anti-PD-1/PD-L1 antibodies in UBC (eg, ABATE, ARCADIA, PemCab, ICONIC) Emerging targets (eg, ICOS, ATR) and other novel agents (eg, feladilimab, berzosertib) and strategies in clinical development for patients with UBC N=37 --> 25
- |||||||||| LY3076226 / Eli Lilly
Enrollment closed, Trial primary completion date, Metastases: A Study of LY3076226 in Participants With Advanced or Metastatic Cancer (clinicaltrials.gov) - Apr 25, 2018
P1, N=37, Active, not recruiting,
Active, not recruiting --> Completed | Trial completion date: Sep 2018 --> Mar 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2018 --> Mar 2018
|
